Virus-Mimicking Polymer Nanocomplexes Co-Assembling HCV E1E2 and Core Proteins with TLR 7/8 Agonist—Synthesis, Characterization, and In Vivo Activity
Source abstract
Abstract
Hepatitis C virus (HCV) is a major public health concern, and the development of an effective HCV vaccine plays an important role in the effort to prevent new infections. Supramolecular co-assembly and co-presentation of the HCV envelope E1E2 heterodimer complex and core protein presents an attractive vaccine design strategy for achieving effective humoral and cellular immunity. With this objective, the two antigens were non-covalently assembled with an immunostimulant (TLR 7/8 agonist) into virus-mimicking polymer nanocomplexes (VMPNs) using a biodegradable synthetic polyphosphazene delivery vehicle. The resulting assemblies were characterized using dynamic light scattering and asymmetric flow field-flow fractionation methods and directly visualized in their vitrified state by cryogenic electron microscopy. The in vivo superiority of VMPNs over the individual components and an Alum-formulated vaccine manifests in higher neutralizing antibody titers, the promotion of a balanced IgG response, and the induction of a cellular immunity—CD4+ T cell responses to core proteins. The aqueous-based spontaneous co-assembly of antigens and immunopotentiating molecules enabled by a synthetic biodegradable carrier offers a simple and effective pathway to the development of polymer-based supramolecular nanovaccine systems.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Hepatitis Viruses Studies and Epidemiology · Hepatitis C virus research · Hepatitis B Virus Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute for Bioscience and Biotechnology Research, University of Maryland Rockville, Rockville, MD 20850, USA
Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA
Department of Microbiology & Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Funding
National Institutes of Health
References (94)
Show source-provided references
1. (2024, April 09). WHO Hepatitis C Key Facts. Available online: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.
2. Hepatitis C virus and hepatocellular carcinoma: Carcinogenesis in the era of direct-acting antivirals10.1016/j.coviro.2024.101423 ↗
3. Costa, G.L., and Sautto, G.A. (2024). Exploring T-Cell Immunity to Hepatitis C Virus: Insights from Different Vaccine and Antigen Presentation Strategies. Vaccines, 12.10.3390/vaccines12080890 ↗
4. Hepatitis C virus recurrence in two patients who achieved sustained viral response with interferon-free direct-acting antiviral therapy: Reinfection or relapse?10.1007/s12328-019-01001-w ↗
5. Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals10.1097/QAD.0000000000002103 ↗
6. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort10.1016/j.jhep.2018.07.025 ↗
7. WHO (2024). Global Hepatitis Report 2024, World Health Organization.
8. Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase10.1128/jvi.69.1.198-205.1995 ↗
9. Expression and identification of hepatitis C virus polyprotein cleavage products10.1128/jvi.67.3.1385-1395.1993 ↗
10. Challenges and Promise of a Hepatitis C Virus Vaccine10.1101/cshperspect.a036947 ↗
11. Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer10.1073/pnas.2015149118 ↗
12. Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate10.1073/pnas.2112008119 ↗
13. Toth, E.A., Chagas, A., Pierce, B.G., and Fuerst, T.R. (2021). Structural and Biophysical Characterization of the HCV E1E2 Heterodimer for Vaccine Development. Viruses, 13.10.3390/v13061027 ↗
14. Identification of a novel hepatitis C virus genotype from Punjab, India: Expanding classification of hepatitis C virus into 8 genotypes10.1093/infdis/jiy401 ↗
15. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: Data from multiple cohorts10.7326/0003-4819-158-4-201302190-00003 ↗
16. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C10.1073/pnas.0607026104 ↗
17. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses10.1002/hep.27013 ↗
18. Neutralizing antibody response during acute and chronic hepatitis C virus infection10.1073/pnas.0403519101 ↗
19. Cellular immunogenicity of a multi-epitope peptide vaccine candidate based on hepatitis C virus NS5A, NS4B and core proteins in HHD-2 mice10.1016/j.jviromet.2013.01.003 ↗
20. Protective T Cell and Antibody Immune Responses against Hepatitis C Virus Achieved Using a Biopolyester-Bead-Based Vaccine Delivery System10.1128/CVI.00687-15 ↗
21. HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses10.1016/j.bbrc.2006.12.232 ↗
22. Guest, J.D., and Pierce, B.G. (2021). Structure-Based and Rational Design of a Hepatitis C Virus Vaccine. Viruses, 13.10.3390/v13050837 ↗
23. Production of virus-like particles for vaccines10.1016/j.nbt.2017.07.010 ↗
24. Gupta, R., Arora, K., Roy, S.S., Joseph, A., Rastogi, R., Arora, N.M., and Kundu, P.K. (2023). Platforms, advances, and technical challenges in virus-like particles-based vaccines. Front. Immunol., 14.10.3389/fimmu.2023.1123805 ↗
25. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells10.1128/JVI.72.5.3827-3836.1998 ↗
26. Masavuli, M.G., Wijesundara, D.K., Torresi, J., Gowans, E.J., and Grubor-Bauk, B. (2017). Preclinical Development and Production of Virus-Like Particles as Vaccine Candidates for Hepatitis C. Front. Microbiol., 8.10.3389/fmicb.2017.02413 ↗
27. Progress in the development of vaccines for hepatitis C virus infection10.3748/wjg.v21.i42.11984 ↗
28. Gomez-Escobar, E., Roingeard, P., and Beaumont, E. (2023). Current Hepatitis C Vaccine Candidates Based on the Induction of Neutralizing Antibodies. Viruses, 15.10.3390/v15051151 ↗
29. Christiansen, D., Earnest-Silveira, L., Grubor-Bauk, B., Wijesundara, D.K., Boo, I., Ramsland, P.A., Vincan, E., Drummer, H.E., Gowans, E.J., and Torresi, J. (2019). Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery. Sci. Rep., 9.10.1038/s41598-019-45461-z ↗
30. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice10.1053/jhep.2001.26523 ↗
31. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates10.1128/JVI.78.13.6995-7003.2004 ↗
32. Large scale production of a mammalian cell derived quadrivalent hepatitis C virus like particle vaccine10.1016/j.jviromet.2016.06.012 ↗
33. Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line10.1099/jgv.0.000493 ↗
34. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine10.4049/jimmunol.166.5.3589 ↗
35. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers10.4161/hv.5.3.6614 ↗
36. Virus-Mimicking Polymer Nanoparticles Targeting CD169+ Macrophages as Long-Acting Nanocarriers for Combination Antiretrovirals10.1021/acsami.1c17415 ↗
37. Virus-mimicking nanosystems: From design to biomedical applications10.1039/D3CS00138E ↗
38. Development of a virus-mimicking nanocarrier for drug delivery systems: The bio-nanocapsule10.1016/j.addr.2015.10.003 ↗
39. Li, X., Liu, S., Yin, P., and Chen, K. (2022). Enhanced immune responses by virus-mimetic polymeric nanostructures against infectious diseases. Front. Immunol., 12.10.3389/fimmu.2021.804416 ↗
40. Modular core-shell polymeric nanoparticles mimicking viral structures for vaccination10.1016/j.jconrel.2018.11.006 ↗
41. Current progress of virus-mimicking nanocarriers for drug delivery10.7150/ntno.21723 ↗
42. Viruses, Artificial Viruses and Virus-Based Structures for Biomedical Applications10.1002/adhm.201501000 ↗
43. Design of Virus-Mimicking Polyelectrolyte Complexes for Enhanced Oral Insulin Delivery10.1016/j.xphs.2019.05.034 ↗
44. Virus-mimetic polymer nanoparticles displaying hemagglutinin as an adjuvant-free influenza vaccine10.1016/j.biomaterials.2018.08.036 ↗
45. Effect of Environmental Factors on Hydrolytic Degradation of Water-Soluble Polyphosphazene Polyelectrolyte in Aqueous Solutions10.1021/bm100395u ↗
46. Polyphosphazene immunoadjuvants: Historical perspective and recent advances10.1016/j.jconrel.2020.12.001 ↗
47. Chand, D.J., Magiri, R.B., Wilson, H.L., and Mutwiri, G.K. (2021). Polyphosphazenes as Adjuvants for Animal Vaccines and Other Medical Applications. Front. Bioeng. Biotechnol., 9.10.3389/fbioe.2021.625482 ↗
48. Directly visualizing individual polyorganophosphazenes and their single-chain complexes with proteins10.1038/s43246-024-00476-6 ↗
49. Immunopotentiating Polyphosphazene Delivery Systems: Supramolecular Self-Assembly and Stability in the Presence of Plasma Proteins10.1021/acs.molpharmaceut.3c00916 ↗
50. Nano-Assembled Polyphosphazene Delivery System Enables Effective Intranasal Immunization with Nipah Virus Subunit Vaccine10.1021/acsabm.4c00441 ↗
51. Molecular-Level Interactions of Polyphosphazene Immunoadjuvants and Their Potential Role in Antigen Presentation and Cell Stimulation10.1021/acs.biomac.6b01251 ↗
52. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants10.1586/14760584.2013.811208 ↗
53. TLR-7 and -8 agonists as vaccine adjuvants10.1586/erv.11.26 ↗
54. Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants10.1016/j.addr.2021.05.013 ↗
55. Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants10.4049/immunohorizons.1700063 ↗
56. Fiji: An open-source platform for biological-image analysis10.1038/nmeth.2019 ↗
57. How to calculate sample size in animal studies?10.4103/0976-500X.119726 ↗
58. Hepatitis C reinfection after sustained virological response10.1016/j.jhep.2016.01.001 ↗
59. Supramolecular assembly of Toll-like receptor 7/8 agonist into multimeric water-soluble constructs enables superior immune stimulation in vitro and in vivo10.1021/acsabm.0c00189 ↗
60. An overview on field-flow fractionation techniques and their applications in the separation and characterization of polymers10.1016/j.progpolymsci.2008.11.001 ↗
61. AF4/MALS/QELS/DRI characterization of regular star polymers and their “span analogs”10.1039/C4AN01105H ↗
62. In Vivo and In Vitro Potency of Polyphosphazene Immunoadjuvants with Hepatitis C Virus Antigen and the Role of Their Supramolecular Assembly10.1021/acs.molpharmaceut.0c00487 ↗
63. Understanding the invisible hands of sample preparation for cryo-EM10.1038/s41592-021-01130-6 ↗
64. Atomic-resolution protein structure determination by cryo-EM10.1038/s41586-020-2833-4 ↗
65. Single-particle cryo-EM-How did it get here and where will it go10.1126/science.aat4346 ↗
66. Visualizing large RNA molecules in solution10.1261/rna.027557.111 ↗
67. Electron Microscopy Studies of Soft Nanomaterials10.1021/acs.chemrev.2c00461 ↗
68. Cryo-EM of Helical Polymers10.1021/acs.chemrev.1c00753 ↗
69. 100th Anniversary of Macromolecular Science Viewpoint: Single-Molecule Studies of Synthetic Polymers10.1021/acsmacrolett.0c00523 ↗
70. Cryo Electron Tomography Reveals Confined Complex Morphologies of Tripeptide-Containing Amphiphilic Double-Comb Diblock Copolymers10.1002/anie.200802834 ↗
71. Mechanism of Dissociation Kinetics in Polyelectrolyte Complex Micelles10.1021/acs.macromol.9b01814 ↗
72. Structure–Property Relationships of Oligonucleotide Polyelectrolyte Complex Micelles10.1021/acs.nanolett.8b03132 ↗
73. Marras, A.E., Vieregg, J.R., Ting, J.M., Rubien, J.D., and Tirrell, M.V. (2019). Polyelectrolyte Complexation of Oligonucleotides by Charged Hydrophobic—Neutral Hydrophilic Block Copolymers. Polymers, 11.10.3390/polym11010083 ↗
74. Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles10.1016/j.virol.2007.05.038 ↗
75. T-cell quality in memory and protection: Implications for vaccine design10.1038/nri2274 ↗
76. Andrianov, A.K., and Fuerst, T.R. (2021). Immunopotentiating and Delivery Systems for HCV Vaccines. Viruses, 13.10.3390/v13060981 ↗
77. Superior immunogenicity of HCV envelope glycoproteins when adjuvanted with cyclic-di-AMP, a STING activator or archaeosomes10.1016/j.vaccine.2017.10.072 ↗
78. Adjuvants for influenza vaccine10.1016/S0923-2494(98)80037-0 ↗
79. Current research on respiratory viral infections: Fourth International Symposium10.1016/S0166-3542(02)00055-4 ↗
80. Safety and Immunogenicity of a randomized Phase I prime-boost trial with ALVAC-HIV (vCP205) and Oligomeric gp160 MN/LAI-2 Adjuvanted in Alum or Polyphosphazene10.1093/infdis/jiw059 ↗
81. Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene10.1186/1742-4690-9-S2-O50 ↗
82. Laera, D., HogenEsch, H., and O’Hagan, D.T. (2023). Aluminum Adjuvants—‘Back to the Future’. Pharmaceutics, 15.10.3390/pharmaceutics15071884 ↗
83. Zhang, T., He, P., Guo, D., Chen, K., Hu, Z., and Zou, Y. (2023). Research Progress of Aluminum Phosphate Adjuvants and Their Action Mechanisms. Pharmaceutics, 15.10.3390/pharmaceutics15061756 ↗
84. Mechanisms of Antigen Adsorption onto an Aluminum-Hydroxide Adjuvant Evaluated by High-Throughput Screening10.1016/j.xphs.2016.03.032 ↗
85. Nano alum: A new solution to the new challenge10.1080/21645515.2022.2060667 ↗
86. Physical and chemical changes in Alhydrogel™ damaged by freezing10.1016/j.vaccine.2018.10.023 ↗
87. Particulate inorganic adjuvants: Recent developments and future outlook10.1111/jphp.12352 ↗
88. Structure-based design of hepatitis C virus E2 glycoprotein improves serum binding and cross-neutralization10.1128/JVI.00704-20 ↗
89. Key roles of adjuvants in modern vaccines10.1038/nm.3409 ↗
90. Kayesh, M.E.H., Kohara, M., and Tsukiyama-Kohara, K. (2023). TLR agonists as vaccine adjuvants in the prevention of viral infections: An overview. Front. Microbiol., 14.10.3389/fmicb.2023.1249718 ↗
91. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells10.1128/JVI.00228-07 ↗
92. Pierce, B.G., Felbinger, N., Metcalf, M., Toth, E.A., Ofek, G., and Fuerst, T.R. (2024). Hepatitis C Virus E1E2 Structure, Diversity, and Implications for Vaccine Development. Viruses, 16.10.20944/preprints202403.1439.v1 ↗
93. Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response10.1128/jvi.00523-22 ↗
94. Poly(dichlorophosphazene) as a precursor for biologically active polyphosphazenes: Synthesis, characterization, and stabilization10.1021/ma0355655 ↗